CLRB icon

Cellectar Biosciences

0.2920 USD
-0.0233
7.39%
At close Apr 1, 4:00 PM EDT
Pre-market
0.2911
-0.0009
0.31%
1 day
-7.39%
5 days
-22.96%
1 month
5.72%
3 months
-10.13%
6 months
-85.96%
Year to date
-10.13%
1 year
-92.55%
5 years
-97.65%
10 years
-99.99%
 

About: Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.

Employees: 11

0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

367% more call options, than puts

Call options by funds: $14K | Put options by funds: $3K

120% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 5

14% less funds holding

Funds holding: 35 [Q3] → 30 (-5) [Q4]

26.78% less ownership

Funds ownership: 39.13% [Q3] → 12.35% (-26.78%) [Q4]

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

95% less capital invested

Capital invested by funds: $30M [Q3] → $1.53M (-$28.5M) [Q4]

100% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 0 (-2) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for CLRB.

Financial journalist opinion

Based on 4 articles about CLRB published over the past 30 days

Positive
Zacks Investment Research
2 weeks ago
Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year?
Here is how Cellectar Biosciences, Inc. (CLRB) and Cencora (COR) have performed compared to their sector so far this year.
Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year?
Neutral
Seeking Alpha
2 weeks ago
Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript
Cellectar Biosciences Inc. (NASDAQ:CLRB ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Anne Marie Fields – Managing Director-Precision AQ Jim Caruso – President and Chief Executive Officer Chad Kolean – Chief Financial Officer Jarrod Longcor – Chief Operating Officer Conference Call Participants Jonathan Aschoff – ROTH Operator Ladies and gentlemen, thank you for standing by, and welcome. At this time all participants are in listen-only mode.
Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
2 weeks ago
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a treatment for Waldenström macroglobulinemia (WM)
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
Neutral
GlobeNewsWire
3 weeks ago
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025
FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report financial results for the full year ended December 31, 2024, and provide a corporate update on March 13, 2025, at 8:30 a.m. Eastern Time.
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025
Neutral
GlobeNewsWire
1 month ago
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
FLORHAM PARK, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually. Details are as follows:
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Neutral
GlobeNewsWire
2 months ago
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference
Oral Presentation Presented at ASH 2024 Showed Iopofosine I 131 Achieved an 83.6% ORR and Exceeded Primary and Secondary Efficacy Endpoints in Phase 2 CLOVER-WaM Study for Relapsed/Refractory Waldenstrom's Macroglobulinemia
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference
Positive
Finbold
3 months ago
Wall Street's top 5 stocks with the biggest upside in 2025
As 2024 is nearing its end, investors with a time machine are looking to visit December 2023 and take their long positions in Nvidia (NASDAQ: NVDA), Tesla (NASDAQ: TSLA), Super Micro Computer (NASDAQ: SMCI) – though with a sell order placed for April – and myriad Chinese stocks, again, with a sell order for October 1.
Wall Street's top 5 stocks with the biggest upside in 2025
Negative
Benzinga
3 months ago
Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options
On Tuesday, Cellectar Biosciences, Inc.  CLRB unveiled a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform, which targets cancer.
Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options
Neutral
GlobeNewsWire
3 months ago
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
Neutral
Business Wire
4 months ago
NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)
BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes, LLC today announced the signing of a strategic Master Supply Agreement with Cellectar Biosciences, Inc. (NASDAQ: CLRB) under which Cellectar will acquire and integrate NorthStar's n.c.a. Ac-225 into Cellectar's proprietary Phospholipid Ethers (PLE) delivery platform to expand the platform's capability to produce a diverse range of radiotherapeutic molecules. NorthStar is a global innovator in the development, production, and commer.
NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)
Charts implemented using Lightweight Charts™